Equities

Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.44
  • Today's Change0.00 / 0.00%
  • Shares traded337.53k
  • 1 Year change-73.33%
  • Beta0.2440
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.

  • Revenue in USD (TTM)17.32m
  • Net income in USD-19.85m
  • Incorporated2016
  • Employees102.00
  • Location
    Immunoprecise Antibodies Ltd3204-4464 Markham St.VICTORIA V8Z 7X8CanadaCAN
  • Phone+1 (604) 806-0626
  • Fax+1 (250) 483-0309
  • Websitehttps://www.ipatherapeutics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IPA:NMQ since
announced
Transaction
value
Carterra Inc-LSA PlatformDeal completed20 Mar 202420 Mar 2024Deal completed-69.66%--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GT Biopharma Inc0.00-11.35m7.44m2.00--1.35-----7.72-7.720.002.470.00----0.00-82.84-205.36-120.73--------------0.00------63.62------
Coeptis Therapeutics Holdings Inc0.00-16.14m8.26m5.00---------0.5143-0.51430.00-0.01110.00----0.00-284.35-37.29-709.12-38.23------------1.22------43.40------
CV Sciences Inc15.85m-2.53m8.54m42.00--3.40--0.5387-0.0157-0.01570.0980.01391.691.5525.35377,285.70-26.94-43.42-73.44-77.7546.0651.81-15.95-45.680.2530--0.0114---1.24-19.80133.96-20.87----
Integrated BioPharma, Inc.50.32m112.00k9.92m147.00124.890.515922.400.19720.00260.00261.620.63911.954.3210.96342,292.500.433813.150.550519.977.7211.220.22265.871.08--0.0004---0.70060.1357806.25-41.775.96--
Aytu Biopharma Inc81.00m-15.84m10.08m99.00--0.3534--0.1245-2.86-2.8614.634.640.63642.153.08818,202.00-12.45-27.76-25.70-46.0367.3958.88-19.56-56.450.7916-0.05940.3531---24.5861.737.08------
Lotus Pharmaceuticals Inc70.79m1.72m10.10m233.000.06780.0012.620.14270.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Bio Essence Corp593.21k-1.02m10.45m12.00------17.62-0.0278-0.01560.0158-0.04580.3305--21.20---57.09-46.10----25.0533.89-172.74-111.21---59.997.03---11.27-10.94-52.03---48.19--
NDT Pharmaceuticals Inc-100.00bn-100.00bn12.59m1.00--0.0703----------1.12-----------164.47---452.47-------6,891.36----0.00---100.00--87.56------
Immunoprecise Antibodies Ltd17.32m-19.85m12.69m102.00--0.5085--0.7323-0.7501-0.75010.66230.86520.35466.126.16---40.63-26.70-46.68-30.3148.2156.13-114.58-85.720.8189-134.720.3289--18.6517.54-2.32--16.71--
Bright Green Corp0.00-9.92m13.74m5.00--1.38-----0.0538-0.05380.000.05190.00----0.00-47.48---72.55--------------0.0494------52.54------
Talphera Inc398.00k-13.70m15.43m15.00--1.21--38.77-0.6353-0.63230.01850.74910.0187----26,533.33-64.37-22.60-78.11-28.55-----3,443.22-714.87----0.00-----21.26-119.16---34.33--
Cumberland Pharmaceuticals, Inc.37.79m-10.38m16.77m91.00--0.636--0.4439-0.7328-0.73282.671.870.45010.86433.17415,225.80-12.35-7.03-17.75-9.5282.5879.95-27.45-17.641.26-38.850.382---5.856.15-12.73---36.17--
TherapeuticsMD Inc996.00k-4.83m17.53m1.00--0.6335--17.60-0.4348-0.55380.08892.400.0212--0.5048996,000.00-10.31-53.35-13.13-111.6145.0886.67-485.34-236.57----0.00---98.14-39.53-816.85------
Data as of Nov 08 2024. Currency figures normalised to Immunoprecise Antibodies Ltd's reporting currency: US Dollar USD

Institutional shareholders

5.83%Per cent of shares held by top holders
HolderShares% Held
Ingalls & Snyder LLCas of 13 Feb 20241.32m4.72%
Renaissance Technologies LLCas of 30 Jun 202463.91k0.23%
BMO Asset Management Corp.as of 30 Jun 202455.86k0.20%
CIBC World Markets, Inc.as of 30 Jun 202441.20k0.15%
Desjardins Securities, Inc.as of 30 Jun 202427.03k0.10%
Paradice Investment Management LLCas of 31 Mar 202426.98k0.10%
Gradient Capital Advisors LLCas of 30 Sep 202426.81k0.10%
Northern Trust Global Investments Ltd.as of 30 Jun 202425.37k0.09%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202425.37k0.09%
Geode Capital Management LLCas of 30 Sep 202417.48k0.06%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.